Literature DB >> 16835574

Inflammatory bowel disease in children: a pediatrician's perspective.

C Cuffari1.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are common and heterogeneous chronic inflammatory bowel disorders of childhood that account for up to 25% of all patients with inflammatory bowel disease (IBD). In CD, the familial pattern of disease concordance would suggest that genetics contribute to disease etiology. Children are more likely to have proximal small bowel disease complicated by stricture formation, fistulization and the need for surgical intervention. The predisposition for small bowel disease has been associated with mutations of the nucleotide oligomerization domain 2 (NOD2)/Caspase activation and recruitment domain 15 (CARD15) gene on chromosome 16 in 1/3 of patients with CD. Homozygous patients also show an early age at disease onset and a relatively high relative risk for isolated stricturing distal ileal disease. The potential clinical role for NOD2 testing in either the diagnosis or the therapeutic management of patients with CD has yet to be determined. The precise age of onset of CD and UC can be difficult in children. Subclinical phases of disease can be identified through a decrease in weight and height velocity, and a delay in pubertal development. However, a confident distinction between CD and UC also remains a taxonomic dilemma in 25% of pediatric patients with IBD, despite recent technological advances in diagnostic techniques, including gadolinium enhanced magnetic resonance imaging (MRI) and capsule endoscopy, and serological testing. The early introduction of immunomodulators, including azathioprine and 6-mercaptopurine have proven efficacy in maintaining long-term remission without concurrent corticosteroids. The pharmacogenomic of 6-MP metabolism has been shown to be useful in predicting susceptibility to antimetabolite induced toxicity, and possibly allowing physician's to individualize drug therapy to improve clinical response. Novel treatment strategies, including infliximab are being developed in Pediatrics with the aim at improving overall treatment efficacy and potentially avoid surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835574

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  10 in total

Review 1.  Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

Authors:  Kristina L Leinwand; Mark E Gerich; Edward J Hoffenberg; Colm B Collins
Journal:  Inflamm Bowel Dis       Date:  2017-02       Impact factor: 5.325

2.  A retrospective comparison of outcomes for open vs. laparoscopic surgical techniques in pediatric ulcerative colitis.

Authors:  Brent A Willobee; Jennifer A Nguyen; Anthony Ferrantella; Hallie J Quiroz; Anthony R Hogan; Ann-Christina Brady; Samir Pandya; Amber H Langshaw; Juan E Sola; Chad M Thorson; Eduardo A Perez
Journal:  Transl Gastroenterol Hepatol       Date:  2021-07-25

Review 3.  Stem cells as a potential future treatment of pediatric intestinal disorders.

Authors:  Troy A Markel; Paul R Crisostomo; Tim Lahm; Nathan M Novotny; Frederick J Rescorla; Joseph Tector; Daniel R Meldrum
Journal:  J Pediatr Surg       Date:  2008-11       Impact factor: 2.545

Review 4.  Infliximab therapy in children and adolescents with inflammatory bowel disease.

Authors:  Gabor Veres; Robert N Baldassano; Petar Mamula
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Infliximab therapy in pediatric Crohn's disease: a review.

Authors:  Kalyan Ray Parashette; Raghavendra Charan Makam; Carmen Cuffari
Journal:  Clin Exp Gastroenterol       Date:  2010-06-15

6.  Clinical and Pathologic Remission of Pediatric Ulcerative Colitis with Serum-Derived Bovine Immunoglobulin Added to the Standard Treatment Regimen.

Authors:  Rachelle A Soriano; Asuncion G Ramos-Soriano
Journal:  Case Rep Gastroenterol       Date:  2017-05-19

7.  The prevalence and phenotype in Brazilian patients with inflammatory bowel disease.

Authors:  Adalberta Lima Martins; Rhaisa Almeida Volpato; Maria da Penha Zago-Gomes
Journal:  BMC Gastroenterol       Date:  2018-06-18       Impact factor: 3.067

8.  Geographic Distribution, Phenotype and Epidemiological Tendency in Inflammatory Bowel Disease Patients in Romania.

Authors:  Adrian Goldiș; Raluca Lupușoru; Liana Gheorghe; Cristian Gheorghe; Anca Trifan; Daniela Dobru; Cristina Cijevschi; Alina Tanțău; Gabriel Constantinescu; Răzvan Iacob; Ramona Goldiș; Mircea Diculescu
Journal:  Medicina (Kaunas)       Date:  2019-10-20       Impact factor: 2.430

9.  Pediatric ulcerative colitis: current treatment approaches including role of infliximab.

Authors:  Gia M Bradley; Maria Oliva-Hemker
Journal:  Biologics       Date:  2012-06-05

10.  Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients.

Authors:  Eun Sil Kim; Yiyoung Kwon; Yon Ho Choe; Mi Jin Kim
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.